作者
Sjoerd Klarenbeek, Chris W Doornebal, Sjors M Kas, Nicola Bonzanni, Jinhyuk Bhin, Tanya M Braumuller, Ingrid Van der Heijden, Mark Opdam, Philip C Schouten, Kelly Kersten, Roebi de Bruijn, Daniel Zingg, Julia Yemelyanenko, Lodewyk FA Wessels, Karin E de Visser, Jos Jonkers
发表日期
2020/1/1
期刊
Oncoimmunology
卷号
9
期号
1
页码范围
1724049
出版商
Taylor & Francis
简介
Effective treatment of invasive lobular carcinoma (ILC) of the breast is hampered by late detection, invasive growth, distant metastasis, and poor response to chemotherapy. Phosphoinositide 3-kinase (PI3K) signaling, one of the major druggable oncogenic signaling networks, is frequently activated in ILC. We investigated treatment response and resistance to AZD8055, an inhibitor of mammalian target of rapamycin (mTOR), in the K14-cre;Cdh1Flox/Flox;Trp53Flox/Flox (KEP) mouse model of metastatic ILC. Inhibition of mTOR signaling blocked the growth of primary KEP tumors as well as the progression of metastatic disease. However, primary tumors and distant metastases eventually acquired resistance after long-term AZD8055 treatment, despite continued effective suppression of mTOR signaling in cancer cells. Interestingly, therapeutic responses were associated with increased expression of genes related to …
引用总数
20212022202320248311